Shenkang injection protects against renal fibrosis by reducing perforin expression through the STING/TBK1/IRF3 signaling pathways in natural killer cells

Hao, Junfeng; Guan, Jibin; Feng, Jingwen; Li, Dongyang; Cao, Shiyu; Li, Yuxuan; Liao, Yong; Sun, Xiaotian; Liu, Dajun; Li, Xiaoyü

doi:10.1016/j.phymed.2022.154206

Cited by 12 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we observed higher baseline serum IL-6 levels in patients who evolved with long-term anemia. Our findings are in line with recent studies in which patients with CKD have high values of IL-6 [40], IFN-γ [41], and CRP [42].…”

Section: Plos Onesupporting

confidence: 93%

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease

et al. 2023

View full text Add to dashboard Cite

Background Anemia is common in chronic kidney disease (CKD) and is associated with outcomes. In addition, serum soluble Fas (sFas) levels are related to anemia and erythropoietin (EPO) resistance. Objectives Firstly, to compare clinical data and serum levels of sFas, EPO, and pro-inflammatory markers between patients with non-dialytic CKD (NDD-CKD) and healthy subjects. Subsequently, to compare and evaluate the relationship of serum EPO, sFas levels with anemia, and outcomes in patients with NDD-CKD over a long follow-up period. Methods We performed a retrospective study in 58 NDD-CKD patients compared with 20 healthy subjects on complete blood count, kidney function, serum EPO, sFas, and inflammatory markers (CRP, IL- 6, and IFN-γ) at baseline. We then compared the same baseline data between patients with NDD-CKD who evolved to anemia and those who did not have anemia over the follow-up. We also evaluated the frequency of outcomes in patients with CKD with higher sFas levels. Finally, we performed a multivariate analysis of factors associated with CKD anemia. Results There were lower eGFR and Hb but higher serum inflammatory markers, sFas levels, sFas/eGFR, and EPO/Hb ratios in patients with NDD-CKD. Comparatively, on the other hand, NDD-CKD patients with anemia had lower eGFR but were older, had more diabetes, and had higher sFas/ eGFR, EPO/Hb ratios, and serum levels of IL-6 and sFas than NDD-CKD without anemia for an extended period. In addition, there was an association in a multivariate analysis of diabetes, age, and sFas levels with kidney anemia. Furthermore, there were higher frequencies of outcomes in increased serum sFas levels. Conclusion As an elective risk factor, serum sFas levels, in addition to age and diabetes, were independently associated with kidney anemia for an extended period. Thus, more studies are necessary to analyze the proper relationship of sFas with kidney anemia and its outcomes and therapy in CKD.

show abstract

Section: Plos Onesupporting

confidence: 93%

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease

et al. 2023

View full text Add to dashboard Cite

show abstract

“…On the one hand, pharmacological studies have found that SKI can decrease proteinuria by effectively alleviating anemia and renal microcirculation, thus inhibiting the pathological proliferation of kidneys, which is conducive to reducing the damage to the kidneys, promoting the repair of damaged tissues, eventually improving renal function ( 15 ). On the other hand, SKI aims to reduce the infiltration of inflammatory cells by alleviating glomerulosclerosis and interstitial fibrosis, thus reducing the level of serum creatinine and blood urea nitrogen ( 16 ).…”

Section: Introductionmentioning

confidence: 99%

Shenkang injection combined with alprostadil for chronic renal failure: A systematic review and meta-analysis

Xie

Zhang

et al. 2023

Front. Med.

View full text Add to dashboard Cite

ObjectiveTo systematically evaluate the clinical efficacy and safety of Shenkang injection (SKI) combined with alprostadil in the treatment of chronic renal failure (CRF).MethodRandomized controlled trials (RCTs) of Shenkang injection combined with alprostadil in CRF treatment were investigated by retrieving a total of 7 databases including CNKI, Wanfang database, VIP, CBM, PubMed, Embase and Cochrane Library, with the search time ranging from 2012 to now. Revman 5.2 software was used for data analysis, and Cochrane bias risk tool was used to evaluate the quality of the included literature. The final results were represented by relative risk (RR), mean difference (MD) and 95% confidence interval (95% CI).ResultsA total of 20 RCTs and 1,573 patients were included in this study. Meta-analysis showed that the overall response rate (ORR) of the treatment group was superior to the control group [RR = 0.20, 95% CI (0.16, 0.25), P < 0.00001]. Compared with the control group, the treatment group achieved favorable improvement in terms of the creatinine clearance rate (Ccr) [MD = 9.48, 95% CI (8.73, 10.24), P < 0.00001], serum creatinine (Scr) [MD = −55.12, 95% CI (−63.42, −46.82), P < 0.00001], quantitative urine protein (Upro) [MD = −0.48, 95% CI (−0.53, −0.43), P < 0.00001], and blood urea nitrogen (BUN) [MD=-3.73, 95% CI (−4.08, −3.3) 7, P < 0.00001]. There was no statistical difference in the incidence of adverse reactions in each group.ConclusionCurrently, Shenkang injection combined with alprostadil has been widely used in clinical treatment of CRF due to the certain effect superior to other methods. However, its specific efficacy and safety need to be further verified through numerous large-scale clinical trials.

show abstract

“…In addition, similar results from in vitro experiments verified the above findings. It is proven that Shenkang injection can exert its anti-fibrosis effect by inhibiting the STING pathway ( Hao et al, 2022 ). The increased expression of STING, TBK1 and IRF3 could also be seen in the renal tubular epithelial cells of G2APOL1 (G2 coding variant of apolipoprotein L1) mice, while the collagen deposition decreased significantly after knockout of STING.…”

Section: The Cyclic Gmp-amp Synthase-stimulator Of Interferon Genes S...mentioning

confidence: 99%

The effect of the cyclic GMP-AMP synthase-stimulator of interferon genes signaling pathway on organ inflammatory injury and fibrosis

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

The cyclic GMP-AMP synthase-stimulator of interferon genes signal transduction pathway is critical in innate immunity, infection, and inflammation. In response to pathogenic microbial infections and other conditions, cyclic GMP-AMP synthase (cGAS) recognizes abnormal DNA and initiates a downstream type I interferon response. This paper reviews the pathogenic mechanisms of stimulator of interferon genes (STING) in different organs, including changes in fibrosis-related biomarkers, intending to systematically investigate the effect of the cyclic GMP-AMP synthase-stimulator of interferon genes signal transduction in inflammation and fibrosis processes. The effects of stimulator of interferon genes in related auto-inflammatory and neurodegenerative diseases are described in this article, in addition to the application of stimulator of interferon genes-related drugs in treating fibrosis.

show abstract

Shenkang injection protects against renal fibrosis by reducing perforin expression through the STING/TBK1/IRF3 signaling pathways in natural killer cells

Cited by 12 publications

References 26 publications

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease

Shenkang injection combined with alprostadil for chronic renal failure: A systematic review and meta-analysis

The effect of the cyclic GMP-AMP synthase-stimulator of interferon genes signaling pathway on organ inflammatory injury and fibrosis

Contact Info

Product

Resources

About